ZNF714

Across TCGA pan-cancer cohorts, ZNF714 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF714 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF714 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF714 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, ESCA, and LUSC are the cancer types where ZNF714 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.147	0.679	.001	12	view →
ESCA	DFS	Median	All	0.075	0.504	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.273	0.742	.028	9	view →
UCEC	OS	Median	All	0.961	0.652	.032	6	view →
SKCM	DFS	Median	III,IV	0.015	0.648	<.001	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF714–LUAD (OS)

Open the LUAD breakdown →